Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NN-224
- Development stage
- Preclinical
- Lead developer
- NanoNewron
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
NN-224 is a humanized TNF-α inhibitory nanobody (single-domain antibody) being developed by NanoNewron for the potential treatment of Alzheimer's disease and other neurodegenerative conditions. As a biologic therapeutic, it targets tumor necrosis factor-alpha (TNF-α), a pro-inflammatory cytokine that plays a central role in neuroinflammation and the progression of neurodegenerative diseases. NN-224 has demonstrated potent TNF-α inhibitory activity with an IC50 of 64.31 pM and exhibits high humanness and solubility scores. It is currently in preclinical development, positioned as a lead candidate alongside NN-223, and is designed to be compatible with NanoNewron's blood-brain barrier (BBB) crossing technology (NewroBus) for effective CNS delivery.
- Other names
- TNF-α inhibitory nanobodyTNF-alpha inhibitory nanobody
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on NN-224.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NN-224.